Sezary Syndrome Market Size & Share, by Treatment Type (Standard Treatment, Advance Treatment); Diagnosis (Immunophenotyping, T-Cell Receptor Gene Rearrangement Test); Drug Class (Monoclonal Antibody, Retinoid, Histone Deacetylase Inhibitor, Biologic Response Modifier, Antibody-Drug Conjugate); Therapy Type (Radiation therapy, Chemotherapy, Immunotherapy); End-user (Hospitals, Homecare, Specialty Clinics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4996
  • Published Date: Jun 02, 2023
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2023 - 2035

Sezary Syndrome Market size is anticipated to reach USD 1.1 Billion by 2035, registering 8% CAGR from 2023 to 2035. In the year 2022, the industry size of sezary syndrome was USD 690 Million. A sezary syndrome is a severe form of cutaneous T-cell lymphoma (CTCL), which is increasing in prevalence worldwide. Approximately six CTCL cases occur per million in the general population every year, age-adjusted. In most cases of Sézary syndrome, people live for at least five years after the disease develops. A rise in cases of this disorder increases demand for treatment and products associated with it.

The number of clinical trials and studies devoted to researching potential treatments for the syndrome is on the rise such as topical corticosteroid, topical mechlorethamine, and topical bexarotene, making it more likely that more effective treatments will be developed. Increasing awareness of the syndrome among medical professionals and improved funding for research into potential treatments have led to increased research efforts.


Global Sezary Syndrome Market
Get more information on this report: Request Free Sample PDF

Global Sezary Syndrome Sector: Growth Drivers and Challenges

Growth Drivers

  • Rise In the Number of Clinical Trials Associated with The Disease - University College London and Merck Sharp & Dohme LLC have been conducting Phase II clinical trials since January 2019. The study aims to assess the effectiveness of Pembrolizumab combined with radiotherapy for patients with relapsed or refractory mycosis fungoides/Sezary syndrome.
  • Emergence of Novel Treatments for Sézary Syndrome - An antibody therapy called mogamulizumab targets a protein called CC chemokine receptor (CCR4) for the treatment of Sézary syndrome. Skin-cell lymphoma cells commonly contain this protein. National Institute for Health and Care Excellence will assess whether the treatment is eligible for NHS funding.
  • A Rise in Biomarker Research and Development - In the early 21st century, regulations in the field of biomarkers developed rapidly and are closely linked to the development of personalized medicine, which involves tailoring treatment based on the genetic and epigenetic characteristics of an individual. This has enabled a better understanding of Sezary Syndrome and the ability to diagnose and treat the condition more effectively.

Challenges

  • Difficulty of diagnosing and treating syndrome- Sezary Syndrome is a rare form of skin cancer that is often difficult to diagnose due to its vague symptoms. Additionally, treatments for Sezary Syndrome are often complicated, expensive, and not always effective, which can limit the market growth for treatments.
  • Lack of awareness of the condition in emerging economies
  • Limited research and approved treatments available for the disease

Sezary Syndrome Market: Key Insights

Base Year

2022

Forecast Year

2023-2035

CAGR

~8%

Base Year Market Size (2022)

~ USD 690 Million

Forecast Year Market Size (2035)

~ USD 1.1 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Sezary Syndrome Segmentation

Diagnosis (Immunophenotyping, T-Cell Receptor (TCR) Gene Rearrangement Test)

A market share of about 52% is estimated for the T-cell receptor gene rearrangement test segment in 2035. As a result of its high accuracy in detecting malignant cells and its ability to distinguish between benign and malignant cells, the TCR test is crucial in diagnosing and treating this condition. Additionally, the TCR gene rearrangement test is relatively quick and non-invasive, reducing the risk of potential side effects from more invasive tests.

Therapy Type (Radiation Therapy, Chemotherapy, Immunotherapy)

Sezary syndrome market from the radiation therapy segment is expected to gain a significant share of about 46% by 2035 driven by the increasing prevalence of sezary syndrome, increasing awareness about RT, and the introduction of new technologies such as total skin electron beam (TSEB) radiation therapy. Radiation therapy using TSEB aims electrons at the whole body's skin to treat this condition. Additionally, radiation therapy has fewer side effects compared to other treatments and is associated with a higher cure rate.

Our in-depth analysis of the market includes the following segments:

     Treatment Type

  • Standard Treatment
  • Advance Treatment

     Diagnosis

  • Immunophenotyping
  • T-Cell Receptor (TCR) Gene Rearrangement Test

Drug Class

  • Monoclonal Antibody
  • Retinoid
  • Histone Deacetylase Inhibitor
  • Biologic Response Modifier
  • Antibody-Drug Conjugate

     Therapy Type

  • Radiation therapy
  • Chemotherapy
  • Immunotherapy

      End User

  • Hospitals, Homecare, Specialty Clinics

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Global Sezary Syndrome Industry Regional Synopsis

North America Market Forecast

North America sezary syndrome market is expected to hold 37% of the revenue share by 2035. Efforts to improve medical facilities and advance healthcare systems have made treatment options abundant in the region. Doctors in the United States are focused on relieving symptoms and improving quality of life when treating newly diagnosed stage III and stage IV mycosis fungoides, including Sézary syndrome, involving the use of Psoralen and ultraviolet A (PUVA) radiation therapy, as well as ultraviolet B radiation therapy.

Asia Pacific Market Analysis

Approximately 25% of the Sezary syndrome market will come from Asia Pacific by 2035. There has been an increase in awareness regarding the disease in the region, a rise in the availability of drugs approved for approval, and the availability of advanced treatments and technologies. A total of 21 monoclonal antibody drugs have been approved by China (10 locally developed, 11 imported). Drugs of the monoclonal antibody class bind to specific cells or proteins in the body. In treating Sezary Syndrome, they stick to abnormal cells in the skin that cause the disease and reduce inflammation.

Research Nester
Global Sezary Syndrome Market-Size
Get more information on this report: Request Free Sample PDF

Top Featured Companies Dominating the Global Sezary Syndrome Market

top-features-companies
    • GSK plc
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • The Bristol Myers Squibb Company
    • F-Hoffmann La Roche Ltd.
    • Pfizer Inc.
    • Novartis AG
    • Johnson and Johnson Services, Inc.
    • Asher Biotherapeutics, Inc.
    • Be Biopharma
    • Eisai Co., Ltd.
    • Seagen Inc.

In-the-news

In The News

  • The Japan-based Eisai Co., Ltd. has received approval to market and manufacture Remitoro for the treatment of relapsed or refractory PTCL or CTCL. The drug Remitoro is considered a high-need drug.
  • Seagen Inc. has announced new data for ADCETRIS will be presented at the 64th Annual Meeting and Exposition of the American Society of Hematology (ASH). An updated and interim efficacy and safety clinical trial study for ADCETRIS in classical Hodgkin lymphoma (cHL) and other CD30-expressing lymphomas as well as other rare cancers was presented in the abstracts, including five oral presentations.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4996
  • Published Date: Jun 02, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increasing number of patients suffering from sezary syndrome, a rise in healthcare expenditure, and a growing awareness about the disease.

The market size of sezary syndrome is anticipated to attain a CAGR of ~8% over the forecast period, i.e., 2023 – 2035.

The major players in the market are GSK plc, Bristol Myers Squibb Company, F-Hoffmann La Roche Ltd., Pfizer Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by treatment type, diagnosis, drug class, therapy type, end users, and by region.

The T-cell receptor (TCR) gene rearrangement test segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Lack of awareness of the condition in emerging economies and limited research and approved treatments available for the disease.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.
Sezary Syndrome Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying